Medisyn Technologies Awarded Phase I SBIR Grant By Department Of Defense To Discover And Develop Novel NSAIDs With Reduced GI Toxicity

Medisyn Technologies announced that the company was recently awarded a Small Business Innovation Research (SBIR) Phase I grant from the Department of Defense (DoD) to discover and develop new non-steroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal toxicity. NSAIDs devoid of GI toxicity that may be potentially available without a prescription (over-the-counter) enables easier access for deployed military personnel.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on January 29th, 2008